Significance of the cytokine interferon gamma in clinical dermatology

被引:38
作者
Grassegger, A [1 ]
Höpfl, R [1 ]
机构
[1] Salurner Str 15, Innsbruck, Austria
关键词
D O I
10.1111/j.1365-2230.2004.01652.x
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
interferon (IFN)-gamma is considered a key cytokine of innate and adaptive immunity playing pivotal roles in host defence against microbial pathogens and tumours, and exerts profound antiproliferative and antifibrotic effects. In this review we discuss applications and perspectives of IFN-gamma in clinical dermatology, such as papillomavirus and bacterial infections, tumours, atopic dermatitis, and fibrotic conditions such as scleroderma and postradiation fibrosis. Moreover, we give a summary of the pharmacologic properties including main side effects and potential risk factors of IFN-gamma therapy. Although former enthusiasm for IFN-gamma (e.g. in atopic dermatitis) has subsided, this cytokine might remain a promising tool (and target) in clinical dermatology, due to its central immunobiologic functions, better characterization of its kinetics in diseases facilitating optimized treatment schedules, and successful applications in fibrotic conditions such as scleroderma, idiopathic pulmonary and skin postradiation fibrosis.
引用
收藏
页码:584 / 588
页数:5
相关论文
共 31 条
[1]  
Agarwala Sanjiv S., 1996, Current Opinion in Oncology, V8, P167, DOI 10.1097/00001622-199603000-00015
[2]   Cellular responses to interferon-gamma [J].
Boehm, U ;
Klamp, T ;
Groot, M ;
Howard, JC .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :749-795
[3]  
BUNN PA, 1990, J AM ACAD DERMATOL, V20, P395
[4]   PATIENTS WITH CONDYLOMA ACUMINATUM EXHIBIT DECREASED INTERLEUKIN-2 AND INTERFERON GAMMA PRODUCTION AND DEPRESSED NATURAL-KILLER ACTIVITY [J].
CAUDA, R ;
TYRING, SK ;
GROSSI, CE ;
TILDEN, AB ;
HATCH, KD ;
SAMS, WM ;
BARON, S ;
WHITLEY, RJ .
JOURNAL OF CLINICAL IMMUNOLOGY, 1987, 7 (04) :304-311
[5]   Atopic dermatitis: The role of recombinant interferon-γ therapy [J].
Chang T.T. ;
Stevens S.R. .
American Journal of Clinical Dermatology, 2002, 3 (3) :175-183
[6]   Treatment of refractory disseminated Mycobacterium abscessus infection with interferon gamma therapy [J].
Colsky, AS ;
Hanly, A ;
Elgart, G ;
Kerdel, FA .
ARCHIVES OF DERMATOLOGY, 1999, 135 (02) :125-127
[7]   DIFFERENTIAL REGULATION OF GLYCOSAMINOGLYCAN, FIBRONECTIN, AND COLLAGENASE PRODUCTION IN CULTURED HUMAN DERMAL FIBROBLASTS BY INTERFERON-ALPHA, INTERFERON-BETA, AND INTERFERON-GAMMA [J].
DUNCAN, MR ;
BERMAN, B .
ARCHIVES OF DERMATOLOGICAL RESEARCH, 1989, 281 (01) :11-18
[8]   CLINICAL HEALING OF ANTIMONY-RESISTANT CUTANEOUS OR MUCOCUTANEOUS LEISHMANIASIS FOLLOWING THE COMBINED ADMINISTRATION OF INTERFERON-GAMMA AND PENTAVALENT ANTIMONIAL COMPOUNDS [J].
FALCOFF, E ;
TARANTO, NJ ;
REMONDEGUI, CE ;
DEDET, JP ;
CANINI, LM ;
RIPOLL, CM ;
DIMIERDAVID, L ;
VARGAS, F ;
GIMENEZ, LA ;
BERNABO, JG ;
BOTTASSO, OA .
TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE, 1994, 88 (01) :95-97
[9]   THE MOLECULAR CELL BIOLOGY OF INTERFERON-GAMMA AND ITS RECEPTOR [J].
FARRAR, MA ;
SCHREIBER, RD .
ANNUAL REVIEW OF IMMUNOLOGY, 1993, 11 :571-611
[10]   TREATMENT OF SYSTEMIC-SCLEROSIS WITH RECOMBINANT INTERFERON-GAMMA - A PHASE I/II CLINICAL-TRIAL [J].
FREUNDLICH, B ;
JIMENEZ, SA ;
STEEN, VD ;
MEDSGER, TA ;
SZKOLNICKI, M ;
JAFFE, HS .
ARTHRITIS AND RHEUMATISM, 1992, 35 (10) :1134-1142